Dogodan Therapeutics is a cutting-edge biotech company based in Westford, MA, specializing in the development of innovative treatments for a wide range of lung-related diseases, including lung adenocarcinoma, lung squamous cell carcinoma, and uveal melanoma. With a focus on genetic loci derived from GWAS studies, they employ localized epigenetic remodeling and therapeutic strategies to combat these conditions, aiming to revolutionize medicine in areas lacking effective and safe treatments.
Driven by their mission to harness the potential of technology, Dogodan Therapeutics has created a groundbreaking genomic medicine platform that integrates various tools, such as protein and nucleic acid structural biology, genomics, bioinformatics, and machine learning. This platform enables the development of custom-designed macromolecular therapeutics, targeting specific loci in the genome. Committed to collaboration, Dogodan Therapeutics actively seeks partnerships with commercial, academic, and non-profit organizations to further their research and advance the field of biomedicine.
Generated from the website